# Researchi Therapeutics Co.

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/researchi-therapeutics-co

- Industry: Biotechnology
- Headquarters: Seoul, South Korea
- Website: www.recerise.com
- Total disclosed funding: $5.4M
- Latest round: Series A (Jun 30, 2022)
- Investors on record: 5

## About

Based in South Korea, and founded in 2000, Researchi Therapeutics Co., Ltd. also known as Recerise, operates as a bio-venture company that specializes in developing treatment strategies for liver diseases. In June 2022, Recerise Therapeutics raised KRW 7 billion in series A funding from Timewise Investment, QUAD Ventures, Partners Investment, Creation Investment Advisory, and CKD Venture Capital. As of June 2023, the company is led by its CEO, Yongbae Kim. 

Recerise Therapeutics Co., Ltd. is developing a liquid biopsy-based companion diagnosis technology for the treatment of liver disease that aligns with the liver's natural functions. The company focuses on the liver's role in immune response and metabolism and provides solutions that address the underlying causes of liver diseases.

## Funding rounds

- Series A, Jun 30, 2022, $5.4M — CKD Venture Capital, Partners Investment, CJ Investment, QUAD Ventures, Creation Investment Advisory

## Investors

- CKD Venture Capital (https://capitalatlas.ai/funds/ckd-venture-capital) — Series A
- Partners Investment (https://capitalatlas.ai/funds/partners-investment) — Series A
- CJ Investment (https://capitalatlas.ai/funds/cj-investment) — Series A
- QUAD Ventures (https://capitalatlas.ai/funds/quad-ventures) — Series A
- Creation Investment Advisory (https://capitalatlas.ai/funds/creation-investment-advisory) — Series A